RBC Life Sciences (OTCMKTS:RBCL) versus Boston Scientific (NYSE:BSX) Head to Head Comparison

RBC Life Sciences (OTCMKTS:RBCL) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares RBC Life Sciences and Boston Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RBC Life Sciences	N/A	N/A	N/A
Boston Scientific	13.55%	19.21%	10.62%

Institutional and Insider Ownership

89.1% of Boston Scientific shares are held by institutional investors. 45.8% of RBC Life Sciences shares are held by insiders. Comparatively, 0.5% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares RBC Life Sciences and Boston Scientific”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RBC Life Sciences	N/A	N/A	N/A	N/A	N/A
Boston Scientific	$16.75 billion	8.56	$1.85 billion	$1.68	57.58

Boston Scientific has higher revenue and earnings than RBC Life Sciences.

Analyst Ratings

This is a summary of recent recommendations for RBC Life Sciences and Boston Scientific, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RBC Life Sciences	0	0	0	0	0.00
Boston Scientific	0	2	23	2	3.00

Boston Scientific has a consensus target price of $120.71, suggesting a potential upside of 24.79%. Given Boston Scientific’s stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than RBC Life Sciences.

Summary

Boston Scientific beats RBC Life Sciences on 9 of the 10 factors compared between the two stocks.

About RBC Life Sciences

RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products in North America, Southeast Asia, and Australia. The company's Nutritional Products segment offers nutritional supplements and personal care products, including herbs, vitamins, and minerals; and natural skin, hair, and body care products through a network of independent distributors and license arrangements. Its products include Stem-Kine, a dietary supplement; Microhydrin and Microhydrin Plus antioxidants; VitAloe, a blend of research-backed ingredients; OliViva, an antioxidant beverage to support immune and cardiovascular system; Organic Spirulina, a nutritious alga that provides range of nutrients and easily digested proteins; and NeuroBright to support brain function, and enhance energy and acuity. This segments products also comprise Colo-Vada Plus, a colon cleansing program; HydraCel to enhance the quality of drinking water; 24 Seven, a multivitamin/mineral supplement; Immune 360 to nourish and support the function of the immune system; and Aloe Gelee gel that provides the soothing and moisturizing. Its Medical Products segment offers wound care products for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. Its products include cleansers, dressings, hydrogels, collagen, calcium alginates, moisture barriers, antimicrobials, and a hydrogel wound dressing with Lidocaine. This segment also offers other wound care products designed to reduce destruction to skin and tissue caused by radiation; and to reduce pain and itching in the skin, and the internal mucosa caused by radiation reactions or reactions to various cancer medications. This segment sells its products under the MPM Medical brand to hospitals, nursing homes, clinics, and pharmacies through a network of medical/surgical supply dealers and pharmaceutical distributors. The company was founded in 1988 and is headquartered in Irving, Texas.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.